Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Oncolytics Biotech

DB:ONYN
Snowflake Description

Moderate growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ONYN
DB
CA$75M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The last earnings update was 34 days ago. More info.


Add to Portfolio Compare Print
  • Oncolytics Biotech has significant price volatility in the past 3 months.
ONYN Share Price and Events
7 Day Returns
3.9%
DB:ONYN
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-20.6%
DB:ONYN
-7.4%
DE Biotechs
-14.2%
DE Market
ONYN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Oncolytics Biotech (ONYN) 3.9% -25% -62.7% -20.6% -77.2% -77.7%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • ONYN underperformed the Biotechs industry which returned -7.4% over the past year.
  • ONYN underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
ONYN
Industry
5yr Volatility vs Market

Value

 Is Oncolytics Biotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Oncolytics Biotech is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Oncolytics Biotech has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Oncolytics Biotech. This is due to cash flow or dividend data being unavailable. The share price is €1.32.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Oncolytics Biotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Oncolytics Biotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:ONYN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in CAD CA$-1.50
TSX:ONC Share Price ** TSX (2020-04-08) in CAD CA$2.05
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Oncolytics Biotech.

DB:ONYN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:ONC Share Price ÷ EPS (both in CAD)

= 2.05 ÷ -1.50

-1.37x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oncolytics Biotech is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Oncolytics Biotech is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Oncolytics Biotech's expected growth come at a high price?
Raw Data
DB:ONYN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.37x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
57.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Oncolytics Biotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Oncolytics Biotech's assets?
Raw Data
DB:ONYN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in CAD CA$0.00
TSX:ONC Share Price * TSX (2020-04-08) in CAD CA$2.05
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:ONYN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:ONC Share Price ÷ Book Value per Share (both in CAD)

= 2.05 ÷ 0.00

-611.94x

* Primary Listing of Oncolytics Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oncolytics Biotech has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at Oncolytics Biotech's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Oncolytics Biotech's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Oncolytics Biotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Oncolytics Biotech has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Oncolytics Biotech expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
57.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Oncolytics Biotech expected to grow at an attractive rate?
  • Oncolytics Biotech's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Oncolytics Biotech's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Oncolytics Biotech's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:ONYN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:ONYN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 57.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:ONYN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:ONYN Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 155 134 105 3
2023-12-31 42 68 32 3
2022-12-31 10 -5 -16 3
2021-12-31 0 -27 -26 3
2020-12-31 0 -27 -25 4
2020-04-08
DB:ONYN Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-12-31 -20 -33
2019-09-30 -17 -19
2019-06-30 -16 -18
2019-03-31 -11 -17
2018-12-31 -12 -17
2018-09-30 -11 -17
2018-06-30 -10 -17
2018-03-31 -16 -17
2017-12-31 -15 -16
2017-09-30 -15 -16
2017-06-30 -15 -16
2017-03-31 -13 -15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Oncolytics Biotech's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Oncolytics Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:ONYN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Oncolytics Biotech Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ONYN Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 3.64 3.64 3.64 1.00
2023-12-31 0.91 1.85 -0.03 2.00
2022-12-31 -0.45 -0.22 -0.67 2.00
2021-12-31 -0.71 -0.59 -0.90 3.00
2020-12-31 -0.71 -0.54 -0.99 4.00
2020-04-08
DB:ONYN Past Financials Data
Date (Data in CAD Millions) EPS *
2019-12-31 -1.50
2019-09-30 -0.95
2019-06-30 -1.02
2019-03-31 -1.03
2018-12-31 -1.06
2018-09-30 -1.10
2018-06-30 -1.11
2018-03-31 -1.16
2017-12-31 -1.12
2017-09-30 -1.20
2017-06-30 -1.27
2017-03-31 -1.15

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Oncolytics Biotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Oncolytics Biotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Oncolytics Biotech has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Oncolytics Biotech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Oncolytics Biotech's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Oncolytics Biotech does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Oncolytics Biotech's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Oncolytics Biotech's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Oncolytics Biotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Oncolytics Biotech Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ONYN Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -33.12 9.56 11.13
2019-09-30 -18.54 7.80 10.83
2019-06-30 -18.35 7.44 11.14
2019-03-31 -17.31 7.27 9.68
2018-12-31 -17.04 7.24 9.42
2018-09-30 -16.96 7.03 8.61
2018-06-30 -16.63 6.87 8.41
2018-03-31 -16.77 6.68 9.28
2017-12-31 -15.62 6.21 8.61
2017-09-30 -16.08 5.87 8.99
2017-06-30 -16.41 5.78 9.41
2017-03-31 -14.64 5.46 7.98
2016-12-31 -15.14 5.52 8.44
2016-09-30 -13.43 5.24 8.36
2016-06-30 -12.92 5.20 7.92
2016-03-31 -14.19 5.49 8.90
2015-12-31 -13.72 5.32 8.60
2015-09-30 -14.01 5.07 9.12
2015-06-30 -15.82 5.00 10.99
2015-03-31 -16.69 4.79 12.07
2014-12-31 -18.62 5.00 13.82
2014-09-30 -20.63 4.99 15.89
2014-06-30 -22.11 5.11 17.32
2014-03-31 -22.41 5.22 17.57
2013-12-31 -23.53 5.39 18.51
2013-09-30 -26.23 5.91 20.65
2013-06-30 -29.36 5.86 23.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Oncolytics Biotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Oncolytics Biotech has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Oncolytics Biotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Oncolytics Biotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Oncolytics Biotech has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Oncolytics Biotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Oncolytics Biotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Oncolytics Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Oncolytics Biotech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Oncolytics Biotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Oncolytics Biotech has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Oncolytics Biotech Company Filings, last reported 3 months ago.

DB:ONYN Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -0.11 0.00 14.15
2019-09-30 3.45 0.00 12.30
2019-06-30 3.79 0.00 12.28
2019-03-31 5.70 0.00 14.21
2018-12-31 6.20 0.00 13.70
2018-09-30 9.05 0.00 16.21
2018-06-30 10.97 0.00 18.74
2018-03-31 4.74 0.00 7.75
2017-12-31 8.28 0.00 11.84
2017-09-30 12.07 0.00 14.03
2017-06-30 14.27 0.00 16.68
2017-03-31 7.27 0.00 10.10
2016-12-31 10.69 0.00 14.12
2016-09-30 15.63 0.00 17.70
2016-06-30 18.59 0.00 20.41
2016-03-31 20.47 0.00 22.32
2015-12-31 24.67 0.00 26.08
2015-09-30 27.72 0.00 30.02
2015-06-30 30.13 0.00 32.08
2015-03-31 27.17 0.00 30.64
2014-12-31 13.82 0.00 16.18
2014-09-30 14.78 0.00 17.04
2014-06-30 16.38 0.00 18.91
2014-03-31 18.20 0.00 22.19
2013-12-31 22.21 0.00 27.22
2013-09-30 27.64 0.00 31.47
2013-06-30 33.84 0.00 38.15
  • Oncolytics Biotech has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Oncolytics Biotech's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Oncolytics Biotech has less than a year of cash runway based on current free cash flow.
  • Oncolytics Biotech has less than a year of cash runway if free cash flow continues to reduce at historical rates of -7.7% each year.
X
Financial health checks
We assess Oncolytics Biotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Oncolytics Biotech has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Oncolytics Biotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Oncolytics Biotech dividends.
If you bought €2,000 of Oncolytics Biotech shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Oncolytics Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Oncolytics Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:ONYN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:ONYN Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Oncolytics Biotech has not reported any payouts.
  • Unable to verify if Oncolytics Biotech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Oncolytics Biotech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Oncolytics Biotech has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Oncolytics Biotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Oncolytics Biotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Oncolytics Biotech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Oncolytics Biotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Matt Coffey
COMPENSATION CA$964,677
TENURE AS CEO 3.3 years
CEO Bio

Dr. Matthew C. Coffey, also known as Matt, Ph.D.,M.B.A., Co-founded Oncolytics Biotech Inc., and has been its Chief Executive Officer and President since January 19, 2017. Dr. Coffey served as Interim Chief Executive Officer and President of Oncolytics Biotech since November 2, 2016 until January 19, 2017. Dr. Coffey served as the Chief Operating Officer of Oncolytics Biotech Inc. since December 2008 until November 2016. He served as Vice President of Product Development from July 1999 to December 2004 and Chief Financial Officer of Oncolytics Biotech Inc., from September 1999 to May 2000 and Project Manager of SYNSORB from March 1999 to July 1999. He served as the Chief Scientific Officer of Oncolytics Biotech Inc., from December 9, 2004 to December 2008. He serves as a Scientific Advisor of Diamond International Group Inc. Dr. Coffey serves as an Independent Medical & Scientific Advisor of Amma Corporation. He has been a Director of Oncolytics Biotech Inc. since May 11, 2011. Dr. Coffey completed his Doctorate Degree in Oncology at the University of Calgary with a focus on the Oncolytics capabilities of the reovirus. The results of his research have been published in various respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal.

CEO Compensation
  • Matt's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Matt's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Oncolytics Biotech management team in years:

2.3
Average Tenure
  • The tenure for the Oncolytics Biotech management team is about average.
Management Team

Matt Coffey

TITLE
President
COMPENSATION
CA$965K
TENURE
3.3 yrs

Kirk Look

TITLE
Chief Financial Officer
COMPENSATION
CA$681K
TENURE
7.4 yrs

Michael Moore

TITLE
Vice President of Investor Relations & Corporate Communications
COMPENSATION
CA$465K

Andrew de Guttadauro

TITLE
Global Head of Business Development & President of Oncolytics Biotech (U.S.) Inc
COMPENSATION
CA$558K
AGE
52

Rita Laeufle

TITLE
Chief Medical Officer
COMPENSATION
CA$836K
TENURE
1.4 yrs

J. Lievonen

TITLE
Consultant
COMPENSATION
CA$26K
TENURE
0.9 yrs

Grey Wilkinson

TITLE
Scientist of Translational Medicine

Dan Von Hoff

TITLE
Consultant
AGE
71
Board of Directors Tenure

Average tenure and age of the Oncolytics Biotech board of directors in years:

4.8
Average Tenure
62
Average Age
  • The tenure for the Oncolytics Biotech board of directors is about average.
Board of Directors

Wayne Pisano

TITLE
Independent Chairman of the Board
COMPENSATION
CA$132K
AGE
64
TENURE
4.8 yrs

Matt Coffey

TITLE
President
COMPENSATION
CA$965K
TENURE
8.9 yrs

Angela Holtham

TITLE
Independent Director
COMPENSATION
CA$115K
AGE
68
TENURE
5.8 yrs

William Rice

TITLE
Independent Director
COMPENSATION
CA$103K
AGE
60
TENURE
4.8 yrs

Deborah Brown

TITLE
Independent Director
COMPENSATION
CA$108K
TENURE
2.4 yrs

Bernd Seizinger

TITLE
Independent Director
COMPENSATION
CA$99K
AGE
62
TENURE
4.8 yrs

Mattine Piccart

TITLE
Member of Scientific Advisory Board
TENURE
2.4 yrs

Aleix Prat

TITLE
Member of Scientific Advisory Board

Pam Sharma

TITLE
Member of Scientific Advisory Board

Leon Kruimer

TITLE
Independent Director
COMPENSATION
CA$28K
AGE
61
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Oncolytics Biotech individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
30. Mar 20 Buy Angela Holtham Individual 27. Mar 20 27. Mar 20 6,000 €1.30 €7,748
10. Jan 20 Sell Deborah Brown Individual 06. Jan 20 06. Jan 20 -14,000 €3.30 €-46,176
03. Oct 19 Buy Bernd Seizinger Individual 03. Oct 19 03. Oct 19 38,000 €0.40 €15,191
02. Oct 19 Buy Matthew Coffey Individual 02. Oct 19 02. Oct 19 10,000 €0.39 €3,898
02. Oct 19 Buy Bernd Seizinger Individual 02. Oct 19 02. Oct 19 38,000 €0.40 €15,137
16. Aug 19 Buy Bernd Seizinger Individual 16. Aug 19 16. Aug 19 25,000 €0.55 €13,631
18. Jun 19 Buy Kirk Look Individual 18. Jun 19 18. Jun 19 1,500 €1.50 €2,247
18. Jun 19 Buy Matthew Coffey Individual 18. Jun 19 18. Jun 19 1,300 €1.51 €1,967
X
Management checks
We assess Oncolytics Biotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Oncolytics Biotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer. It has collaboration with PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

Details
Name: Oncolytics Biotech Inc.
ONYN
Exchange: DB
Founded: 1998
CA$49,211,155
37,090,525
Website: http://www.oncolyticsbiotech.com
Address: Oncolytics Biotech Inc.
1167 Kensington Crescent NW,
Suite 210,
Calgary,
Alberta, T2N 1X7,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX ONC Common Shares The Toronto Stock Exchange CA CAD 08. Nov 1999
NasdaqCM ONCY Common Shares Nasdaq Capital Market US USD 08. Nov 1999
DB ONYN Common Shares Deutsche Boerse AG DE EUR 08. Nov 1999
Number of employees
Current staff
Staff numbers
0
Oncolytics Biotech employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 21:49
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/03
Last earnings filing: 2020/03/05
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.